Latest News and Press Releases

Funding to advance AI-native drug R&D engine and pipelines, including MDR-001, an oral GLP-1 small-molecule in Phase III clinical trials in China.

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter Targets Neve Yarak, Israel, June ...

Tevogen.AI nears PredicTcell completion, expands features to 290+, improves precision ~10%, and begins exploring co-development partnerships.

WARREN, N.J., March 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced performance advancements for its artificial intelligence platform,...

Phase 1/2 RESTORE-MASH trial will evaluate safety, pharmacokinetics, and pharmacodynamics of TGM-312 in healthy volunteers and MASH patients Initial data anticipated H2 2026 LONDON, March 05, 2026 ...

MindRank, artificial intelligence (AI)-empowered drug discovery company, announced FPI in Phase III Trial of an Oral GLP-1 Receptor Agonist MDR-001.

NorthStrive Biosciences Announces Progress Updates to Phase III Timeline for AI-Driven Drug Discovery Program with Yuva Biosciences

MindRank Initiates Phase III "MOBILE" Trial for MDR-001: an Oral GLP-1RA Small Molecule Engineered with AI

NorthStrive Biosciences Advances to Phase III of AI-Driven Drug Discovery Program Toward Validation of Multiple Potential Drug Compounds & Discoveries